KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Inventory (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Inventory for 15 consecutive years, with $3.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Inventory fell 2.78% year-over-year to $3.1 billion; the TTM value through Mar 2026 reached $3.1 billion, down 2.78%, while the annual FY2025 figure was $3.2 billion, 3.68% up from the prior year.
  • Inventory hit $3.1 billion in Q1 2026 for Regeneron Pharmaceuticals, down from $3.2 billion in the prior quarter.
  • Across five years, Inventory topped out at $3.3 billion in Q3 2025 and bottomed at $2.0 billion in Q1 2022.
  • Average Inventory over 5 years is $2.7 billion, with a median of $2.7 billion recorded in 2024.
  • On a YoY basis, Inventory climbed as much as 23.09% in 2022 and fell as far as 8.0% in 2022.
  • Regeneron Pharmaceuticals' Inventory stood at $2.4 billion in 2022, then grew by 7.44% to $2.6 billion in 2023, then rose by 19.64% to $3.1 billion in 2024, then increased by 3.68% to $3.2 billion in 2025, then decreased by 3.04% to $3.1 billion in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $3.1 billion, $3.2 billion, and $3.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.